Entry Detail


General Information

Database ID:TRD03149
Confidence:Very High
Contents:>> tsRNA Information
>> tsRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference



tsRNA Information

tsRNA Name:tRF-Glu-CTC
tsRNA Type:tRF-5
Amino acid and Anticodon:GluCTC
Sequence:N/A
Related Target:VASH1
Predicted Target:N/A
External Links:
MINTbase ID:N/A
tRFdb ID:N/A



tsRNA Association Statistics

Total Associated Disease Number:1
More Information
Network:
(Display the first 15 nodes)



Disease Information

 MeSHDisease Ontology
Disease ID:D008268DOID:10871
Disease Name:Macular Degenerationage related macular degeneration
Category:MeSHDisease Ontology
Type:Eye Diseasesdisease of anatomical entity//genetic disease
Define:Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.A degeneration of macula and posterior pole that is characterized by a loss of vision in the center of the visual field (the macula) resulting from damage to the retina and resulting in blurring of the sharp central vision.
Alias:Age-Related Macular Degeneration//Age-Related Maculopathies//Age-Related Maculopathy//Macular Degeneration, Age-Related//Macular Dystrophy//Maculopathies, Age-Related//Maculopathy//Maculopathy, Age-RelatedAge Related Maculopathies//Age Related Maculopathy//age-related macular degeneration//Senile macular degeneration//Senile macular retinal degeneration



Disease Association Statistics

Total Associated tsRNA Number:62
More Information
Network:
(Display the first 15 nodes)



Evidence Support

Strong Evidence:RT-PCR//Western blot
Weak Evidence:High-throughput sequencing



Reference

[1] PubMed ID:38389841
Disease Name:Macular Degeneration
Tissue:Vessel
Dysfunction Pattern:Up-Regulation
Validated Method:RT-PCR//Western blot//High-throughput sequencing
Description:This study demonstrated the important role of tRF-Glu-CTC in the progression of angiogenesis. Targeting of tRF-Glu-CTC may be an alternative to current anti-VEGF therapy for CNV in AMD and other conditions with angiogenesis.
Comparision:Disease VS Control
Mechanism:Mechanically, under hypoxia condition, angiogenin was involved in the production of tRF-Glu-CTC, which in turn triggered endothelial cell tubulogenesis, migration and promoted the secretion of inflammatory factors via the suppression of vasohibin 1 (VASH1). When downregulating VASH1 expression, the inhibition of tRF-Glu-CTC showed minimal suppression on angiogenesis.